S. aureus is a major human pathogen, with the potential to cause severe invasive diseases. It is a major cause for concern in hospitals and healthcare facilities, where many infections are caused by strains resistant to commonly used antibiotics [MRSA]. Interestingly, S. aureus persistently colonizes about 20% of the human population by binding to skin-like cells within the nasal cavity. Being colonized predisposes an individual towards becoming infected so it is vital that we understand the mechanisms involved.

ClfB was previously shown to promote S. aureus colonization in a human nasal colonization volunteer study. This paper now identifies the mechanism by which ClfB facilitates S. aureus nasal colonization. Purified ClfB bound loricrin with high affinity and this interaction was shown to be crucial for successful colonization of the nose in a mouse model. A knockout mouse lacking loricrin in its skin cells allowed fewer bacterial cells to colonize its nasal passages than a normal mouse. When S. aureus strains that lacked ClfB were used nasal colonization could not be achieved at all. Finally it was shown that soluble loricrin could reduce binding of S. aureus to human nasal skin cells and that nasal administration of loricrin reduced S. aureus colonization of mice.

Rachel McLoughlin, the study's corresponding author and Lecturer at the School of Biochemistry and Immunology at Trinity College Dublin concludes, "Loricrin is a major determinant of S. aureus nasal colonization." This discovery therefore opens new avenues for developing therapeutic strategies to reduce the burden of nasal carriage and consequently infections with this bacterium. This is particularly important given the difficulties associated with treating MRSA infections.